These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35928818)

  • 41. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
    Hu Y; Tu Z; Lei K; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma.
    Dong T; Zhang B; Zhang R; Wang C; Liu X; Wang F; Hao N; Tan K; Chang YZ
    Front Oncol; 2022; 12():963096. PubMed ID: 36237302
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in Glioma.
    Luo X; Wang Q; Tang H; Chen Y; Li X; Chen J; Zhang X; Li Y; Sun J; Han S
    Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676646
    [No Abstract]   [Full Text] [Related]  

  • 44. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
    Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
    Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics.
    Lin WW; Ou GY; Zhao WJ
    J Cell Mol Med; 2021 Nov; 25(21):10111-10125. PubMed ID: 34597473
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ferroptosis-related gene signature predicts prognosis and immunotherapy in glioma.
    Wan RJ; Peng W; Xia QX; Zhou HH; Mao XY
    CNS Neurosci Ther; 2021 Aug; 27(8):973-986. PubMed ID: 33969928
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Single cell RNA sequencing reveals differentiation related genes with drawing implications in predicting prognosis and immunotherapy response in gliomas.
    Zhou Z; Wei J; Yang Z; Bao Y; Jiang W; Lu B; Wang W; Li L
    Sci Rep; 2022 Feb; 12(1):1872. PubMed ID: 35115572
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Functional characterization of TSPAN7 as a novel indicator for immunotherapy in glioma.
    Chen L; Liu H; Li Y; Lin X; Xia S; Wanggou S; Li X
    Front Immunol; 2023; 14():1105489. PubMed ID: 36845098
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adenylate kinase 2 is a biomarker related to the prognosis of glioma and the immune microenvironment.
    Liu Z; Tang C; Teng X; Mohamed ZA; Fan J
    J Clin Lab Anal; 2023 Apr; 37(8):e24892. PubMed ID: 37161605
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Systematic Review of the Tumor-Infiltrating CD8
    Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():734956. PubMed ID: 34603316
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of genes related to low-grade glioma progression and prognosis based on integrated transcriptome analysis.
    Jiang Y; He J; Guo Y; Tao H; Pu F; Li Y
    J Cell Biochem; 2020 Jun; 121(5-6):3099-3111. PubMed ID: 31886582
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CNN3 in glioma: The prognostic factor and a potential immunotherapeutic target.
    Xu H; Chai SS; Lv P; Wang JJ
    Medicine (Baltimore); 2021 Nov; 100(46):e27931. PubMed ID: 34797350
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy.
    Cao W; Lan J; Hu C; Kong J; Xiang L; Zhang Z; Sun Y; Zeng Z; Lei S
    Aging (Albany NY); 2024 Mar; 16(6):5618-5633. PubMed ID: 38499392
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comprehensive Analysis of Phagocytosis-Related Regulators to Aid Prognostic Prediction and Immunotherapy in Patients with Low-Grade Glioma.
    Li J; Huang Q; Mo L
    Dis Markers; 2022; 2022():4142684. PubMed ID: 35510040
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictive value of procollagen c-protease enhancer protein on the prognosis of glioma patients.
    Yu L; Hu X; Zhu H
    Heliyon; 2024 Mar; 10(6):e28089. PubMed ID: 38533063
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FCGR3A Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Lower-Grade Glioma.
    Sun K; Fei X; Xu M; Xu R; Xu M
    J Oncol; 2022; 2022():9499317. PubMed ID: 39280892
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comprehensive bioinformatic analysis of cyclin-dependent kinase 2 (CDK2) in glioma.
    Liu H; Weng J
    Gene; 2022 May; 822():146325. PubMed ID: 35183683
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Abundant expression of ferroptosis-related SAT1 is related to unfavorable outcome and immune cell infiltration in low-grade glioma.
    Mou Y; Zhang L; Liu Z; Song X
    BMC Cancer; 2022 Feb; 22(1):215. PubMed ID: 35227235
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis.
    Ghouzlani A; Lakhdar A; Rafii S; Karkouri M; Badou A
    Sci Rep; 2021 Nov; 11(1):21504. PubMed ID: 34728682
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The pro-invasive factor COL6A2 serves as a novel prognostic marker of glioma.
    Zhu J; Lin Q; Zheng H; Rao Y; Ji T
    Front Oncol; 2022; 12():897042. PubMed ID: 36505882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.